Services / Prostate Cancer - Untreated Tumors
Trial Information
Prostate Cancer: Clinical Trial for men with previously untreated localized tumors before surgery.
- Principal Investigator: Matthew Rettig, M.D.
- Co-Investigators: Jean deKernion, M.D., Arie Belldegrun, M.D., Allan Pantuck, M.D., Robert Reiter, M.D., Stephen Riggs, M.D., Fairooz Kabbinavar, M.D.
This trial is currently accepting new patient applications
Objective:
Neoadjuvant Androgen Depletion in Combination with Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET)
The purpose of this study is to see if we can reduce the size of the tumor before prostatectomy (surgical removal of prostate). To do this, we will use androgen depletion therapy to reduce the amount of male hormone you have. This depletion therapy will be accomplished with two drugs: bicalutamide and a GnRH analog. Bicalutamide, commonly known as Casodex, is given orally and blocks the male hormone testosterone from binding to cancer cells. Since prostate cancer cells require testosterone, this drug can stop the growth of these cells.
The GnRH analog that is also given as part of androgen depletion therapy is given by injection once a month. This is a medicine that affects the reproductive hormones, causing less testosterone to be made by the testicles.
In addition to androgen depletion, you will also take a drug called Vorinostat orally.
Vorinostat has been approved by the FDA and has been shown to be effective in killing cancer cells in some cancers. We also know what side effects it causes. However, it has not been used to treat prostate cancer.
We want to see if the combination of these drugs will decrease the size of the tumor and your prostate gland. This might increase the chance that the tumor can be completely removed.
Trial Design
All study participants will receive treatment drugs for 8 weeks before prostatectomy.
Patient Eligibility
Inclusion Criteria
- Biopsy core that demonstrated > 50% involvement with tumor
Exclusion Criteria
- Laparoscopic Prostatectomy
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
For more information
For additional information on inclusion and exclusion criteria and whether or not you may be a candidate to participate in a trial, call recruitment coordinator Diana Sarkisyan at (310) 206-7793 (dsarkisyan@mednet.ucla.edu) or Nazy Zomorodian, Director for the Clinical Trials Office at (310) 794-7704.
|
